NYSEAMERICAN:AST - Asterias Biotherapeutics News Headlines

$0.94
0.00 (0.00 %)
(As of 05/30/2019)
Today's Range
$0.9450
Now: $0.9450
$0.9450
50-Day Range N/A
52-Week Range
$0.51
Now: $0.9450
$2.05
VolumeN/A
Average Volume136,653 shs
Market Capitalization$52.60 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Headlines

Asterias Biotherapeutics (NYSEAMERICAN AST) News Headlines

Source:
DateHeadline
How Financially Strong Is ASTARTA Holding N.V. (WSE:AST)?How Financially Strong Is ASTARTA Holding N.V. (WSE:AST)?
finance.yahoo.com - June 17 at 1:00 PM
One Thing To Remember About The ASTARTA Holding N.V. (WSE:AST) Share PriceOne Thing To Remember About The ASTARTA Holding N.V. (WSE:AST) Share Price
finance.yahoo.com - May 14 at 3:47 PM
BioTime Announces Closing of Acquisition of Asterias Biotherapeutics Creating Leading Cell Therapy Company - Business WireBioTime Announces Closing of Acquisition of Asterias Biotherapeutics Creating Leading Cell Therapy Company - Business Wire
www.businesswire.com - March 11 at 3:38 PM
BioTime Announces Closing of Acquisition of Asterias Biotherapeutics Creating Leading Cell Therapy CompanyBioTime Announces Closing of Acquisition of Asterias Biotherapeutics Creating Leading Cell Therapy Company
www.marketwatch.com - March 11 at 8:30 AM
SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Asterias Biotherapeutics, Inc. – ASTSHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Asterias Biotherapeutics, Inc. – AST
finance.yahoo.com - February 15 at 10:33 AM
BioTime Provides Business Update Including Information on AgeX, OncoCyte and AsteriasBioTime Provides Business Update Including Information on AgeX, OncoCyte and Asterias
globenewswire.com - February 14 at 11:48 AM
What Makes Asterias Biotherapeutics (AST) a New Buy StockWhat Makes Asterias Biotherapeutics (AST) a New Buy Stock
finance.yahoo.com - February 8 at 12:03 PM
Oncocyte rally carries Asterias Bio, up 39%Oncocyte rally carries Asterias Bio, up 39%
seekingalpha.com - January 29 at 3:39 PM
Asterias OPC1 cells show durable effect after a year in spinal cord injury patientsAsterias' OPC1 cells show durable effect after a year in spinal cord injury patients
seekingalpha.com - January 24 at 3:40 PM
Asterias Biotherapeutics (AST) Reports Top-Line 12-Month Data Update for OPC1 Phase 1/2a Clinical Trial in Severe Spinal Cord Injury - StreetInsider.comAsterias Biotherapeutics (AST) Reports Top-Line 12-Month Data Update for OPC1 Phase 1/2a Clinical Trial in Severe Spinal Cord Injury - StreetInsider.com
www.streetinsider.com - January 24 at 12:02 PM
Asterias Provides Top Line 12 Month Data Update for its OPC1 Phase 1/2a Clinical Trial in Severe Spinal Cord InjuryAsterias Provides Top Line 12 Month Data Update for its OPC1 Phase 1/2a Clinical Trial in Severe Spinal Cord Injury
finance.yahoo.com - January 24 at 12:02 PM
BioTime to Present at 2019 Biotech Showcase Investor Conference on January 7, 2019 - Business WireBioTime to Present at 2019 Biotech Showcase Investor Conference on January 7, 2019 - Business Wire
www.businesswire.com - January 4 at 9:24 AM
BioTime Announces Management Changes Concurrent With Participation at 2019 J.P. Morgan Healthcare Conference and 2019 Biotech ShowcaseBioTime Announces Management Changes Concurrent With Participation at 2019 J.P. Morgan Healthcare Conference and 2019 Biotech Showcase
finance.yahoo.com - January 4 at 9:24 AM
Form 425 Asterias Biotherapeutics Filed by: Asterias Biotherapeutics, Inc. - StreetInsider.comForm 425 Asterias Biotherapeutics Filed by: Asterias Biotherapeutics, Inc. - StreetInsider.com
www.streetinsider.com - December 6 at 10:27 AM
Asterias Biotherapeutics Announces Fourth Patient Dosed in First-in-Human Clinical Study of Immunotherapy VAC2 in Non-Small Cell Lung CancerAsterias Biotherapeutics Announces Fourth Patient Dosed in First-in-Human Clinical Study of Immunotherapy VAC2 in Non-Small Cell Lung Cancer
finance.yahoo.com - November 27 at 11:21 AM
Asterias Biotherapeutics beats by $0.02Asterias Biotherapeutics beats by $0.02
seekingalpha.com - November 10 at 10:26 AM
Asterias Biotherapeutics: 3Q Earnings SnapshotAsterias Biotherapeutics: 3Q Earnings Snapshot
finance.yahoo.com - November 10 at 10:26 AM
Asterias Biotherapeutics (AST) Reports Q3 Loss, Tops Revenue EstimatesAsterias Biotherapeutics (AST) Reports Q3 Loss, Tops Revenue Estimates
finance.yahoo.com - November 10 at 10:26 AM
Asterias Biotherapeutics (AST) Reports Positive Outcome from Data Review from OPC1 Spinal Cord Injury StudyAsterias Biotherapeutics (AST) Reports Positive Outcome from Data Review from OPC1 Spinal Cord Injury Study
www.streetinsider.com - November 2 at 11:16 AM
Asterias Biotherapeutics to Report Third Quarter 2018 Results on November 12, 2018Asterias Biotherapeutics to Report Third Quarter 2018 Results on November 12, 2018
finance.yahoo.com - November 2 at 11:16 AM
Asterias Biotherapeutics Announces Positive Outcome from Data Review from OPC1 Spinal Cord Injury StudyAsterias Biotherapeutics Announces Positive Outcome from Data Review from OPC1 Spinal Cord Injury Study
finance.yahoo.com - October 31 at 10:44 AM
What Kind Of Shareholders Own Asterias Biotherapeutics Inc (NYSEMKT:AST)?What Kind Of Shareholders Own Asterias Biotherapeutics Inc (NYSEMKT:AST)?
finance.yahoo.com - October 23 at 3:40 PM
Asterias Biotherapeutics Announces Facilities and IP License Option AgreementsAsterias Biotherapeutics Announces Facilities and IP License Option Agreements
finance.yahoo.com - October 1 at 10:06 AM
FDA accepts Asterias Biotherapeutics’ Type B request for OPC1 spinal cord injury clinical programFDA accepts Asterias Biotherapeutics’ Type B request for OPC1 spinal cord injury clinical program
seekingalpha.com - September 20 at 11:07 AM
FDA Accepts Asterias Biotherapeutics’ Request to Meet and Discuss Next Phase of Development for OPC1 Spinal Cord Injury Clinical ProgramFDA Accepts Asterias Biotherapeutics’ Request to Meet and Discuss Next Phase of Development for OPC1 Spinal Cord Injury Clinical Program
finance.yahoo.com - September 20 at 11:07 AM
Healthcare Stocks: Is Now The Time To Buy Asterias Biotherapeutics Inc (NYSEMKT:AST)?Healthcare Stocks: Is Now The Time To Buy Asterias Biotherapeutics Inc (NYSEMKT:AST)?
finance.yahoo.com - September 18 at 10:48 AM
Asterias Provides 24 Month Cohort 2 Update for its OPC1 Phase 1/2a Clinical Trial in Severe Spinal Cord InjuryAsterias Provides 24 Month Cohort 2 Update for its OPC1 Phase 1/2a Clinical Trial in Severe Spinal Cord Injury
finance.yahoo.com - September 12 at 10:03 AM
Asterias up 3% after second safety review of VAC2 studyAsterias up 3% after second safety review of VAC2 study
seekingalpha.com - September 4 at 3:33 PM
Two Sites in the UK Currently Enrolling PatientsTwo Sites in the UK Currently Enrolling Patients
globenewswire.com - September 4 at 10:42 AM
Asterias Biotherapeutics Announces Positive Outcome from Second Safety Review Committee Meeting and Open Enrollment for VAC2 Clinical Trial in Non-Small Cell Lung Cancer (NSCLC)Asterias Biotherapeutics Announces Positive Outcome from Second Safety Review Committee Meeting and Open Enrollment for VAC2 Clinical Trial in Non-Small Cell Lung Cancer (NSCLC)
finance.yahoo.com - September 4 at 10:42 AM
Asterias Biotherapeutics’ CEO Michael Mulroy to Participate on Regenerative Medicine Therapies Panel at the B. Riley FBR Healthcare ConferenceAsterias Biotherapeutics’ CEO Michael Mulroy to Participate on Regenerative Medicine Therapies Panel at the B. Riley FBR Healthcare Conference
finance.yahoo.com - August 29 at 10:52 AM
Asterias patients: How they are faringAsterias patients: How they are faring
www.msn.com - August 19 at 10:20 AM
The meticulous making of a stem cell therapyThe meticulous making of a stem cell therapy
www.msn.com - August 19 at 10:20 AM
Asterias Biotherapeutics, Inc. (AST) CEO Mike Mulroy on Q2 2018 Results - Earnings Call TranscriptAsterias Biotherapeutics, Inc. (AST) CEO Mike Mulroy on Q2 2018 Results - Earnings Call Transcript
seekingalpha.com - August 10 at 10:36 AM
Asterias Biotherapeutics Reports Second Quarter Financial Results and Recent Development ProgressAsterias Biotherapeutics Reports Second Quarter Financial Results and Recent Development Progress
finance.yahoo.com - August 10 at 10:36 AM
Asterias Biotherapeutics: 2Q Earnings SnapshotAsterias Biotherapeutics: 2Q Earnings Snapshot
finance.yahoo.com - August 10 at 10:36 AM
Asterias Biotherapeutics (AST) Reports Q2 Loss, Tops Revenue EstimatesAsterias Biotherapeutics (AST) Reports Q2 Loss, Tops Revenue Estimates
finance.yahoo.com - August 10 at 10:36 AM
Asterias Provides 12 Month Cohort 3 and 4 Update for its AST-OPC1 Phase 1/2a Clinical Trial in Severe Spinal Cord InjuryAsterias Provides 12 Month Cohort 3 and 4 Update for its AST-OPC1 Phase 1/2a Clinical Trial in Severe Spinal Cord Injury
finance.yahoo.com - July 31 at 10:36 AM
Asterias Biotherapeutics to Report Second Quarter 2018 Results on August 9, 2018Asterias Biotherapeutics to Report Second Quarter 2018 Results on August 9, 2018
finance.yahoo.com - July 26 at 10:36 AM
Asterias Biotherapeutics (AST) Announces 6-Mo Data Readout for AST-OPC1 Phase 1/2a Clinical Trial in Severe ...Asterias Biotherapeutics (AST) Announces 6-Mo Data Readout for AST-OPC1 Phase 1/2a Clinical Trial in Severe ...
www.streetinsider.com - July 18 at 9:37 AM
Asterias Ischemic Stroke Indication Has The Potential To Add Solid Value To OPC1 ProgramAsterias' Ischemic Stroke Indication Has The Potential To Add Solid Value To OPC1 Program
seekingalpha.com - July 17 at 9:58 AM
Asterias up 9% premarket on updated data on AST-OPC1Asterias up 9% premarket on updated data on AST-OPC1
seekingalpha.com - July 17 at 9:58 AM
Asterias Provides Six Month Data Readout for its AST-OPC1 Phase 1/2a Clinical Trial in Severe Spinal Cord InjuryAsterias Provides Six Month Data Readout for its AST-OPC1 Phase 1/2a Clinical Trial in Severe Spinal Cord Injury
finance.yahoo.com - July 17 at 9:58 AM
Asterias Biotherapeutics Cancer Asset Appears Safe: What This Means For The CompanyAsterias Biotherapeutics' Cancer Asset Appears Safe: What This Means For The Company
seekingalpha.com - July 12 at 3:33 PM
Asterias Biotherapeuticss Cancer Asset Appears Safe: What This Means For The CompanyAsterias Biotherapeutics's Cancer Asset Appears Safe: What This Means For The Company
seekingalpha.com - July 12 at 3:33 PM
Asterias Bio nabs patent rights to method for improving recovery in stroke patients; shares up 13% premarketAsterias Bio nabs patent rights to method for improving recovery in stroke patients; shares up 13% premarket
seekingalpha.com - July 12 at 10:11 AM
Asterias Biotherapeutics Announces New Exclusive License Agreement with The Regents of the University of California for Stroke IP; Second Pre-Clinical Collaboration Initiated to Test the Efficacy of AST-OPC1 for the Treatment of StrokeAsterias Biotherapeutics Announces New Exclusive License Agreement with The Regents of the University of California for Stroke IP; Second Pre-Clinical Collaboration Initiated to Test the Efficacy of AST-OPC1 for the Treatment of Stroke
finance.yahoo.com - July 12 at 10:11 AM
Achillion's 3rd Factor D Inhibitor Enters Clinical StudiesAchillion's 3rd Factor D Inhibitor Enters Clinical Studies
finance.yahoo.com - July 11 at 3:30 PM
Pre-Open Movers 07/11: (AST) (VSAR) (SCYX) Higher; (VOXX) (IOTS) (ANGO) Lower (more...)Pre-Open Movers 07/11: (AST) (VSAR) (SCYX) Higher; (VOXX) (IOTS) (ANGO) Lower (more...)
www.streetinsider.com - July 11 at 9:47 AM
Asterias Biotherapeutics (AST) Reports Positive Outcome from Safety Review Committee for AST-VAC2Asterias Biotherapeutics (AST) Reports Positive Outcome from Safety Review Committee for AST-VAC2
www.streetinsider.com - July 11 at 9:47 AM
This page was last updated on 6/25/2019 by MarketBeat.com Staff

Featured Article: Trade Deficit

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel